High-Voltage Electroporation for IL-12 Plasmid Delivery
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for delivering Interleukin-12 (IL-12) using electroporation to treat cancer, such as melanoma, are not effective in achieving significant tumor regression or improving long-term survival rates due to their reliance on low-voltage, long-pulse electroporation protocols that result in inadequate cytokine expression and toxicity.
Innovation Solution
A method involving the administration of a plasmid encoding IL-12 combined with high-voltage, short-duration electroporation therapy, applied both intratumorally and intramuscularly, to enhance cytokine expression and improve treatment efficacy, including multiple treatment sessions with high-voltage pulses of 1500V/cm for short durations and low-voltage pulses of 100V/cm for longer durations.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If low-voltage, long-pulse electroporation is used to deliver plasmid DNA, then cell membrane permeabilization occurs, but cytokine expression is inadequate and treatment efficacy is limited
Solution Approach 1:
The patent changes the electroporation parameters from conventional low-voltage/long-pulse to high-voltage/short-pulse configuration. Specifically, it uses voltage pulses of 1500V/cm for 100 microseconds, which creates sufficient membrane permeabilization to enhance plasmid DNA uptake and subsequent cytokine expression, thereby resolving the contradiction between treatment efficacy and cytokine expression level
2Productivity
If high-voltage, short-duration electroporation pulses are applied, then plasmid DNA uptake is enhanced and cytokine expression increases, but the complexity of the treatment protocol increases
Solution Approach 1:
The patent employs periodic application of high-voltage electroporation pulses (1500V/cm for 100 microseconds) at specific time intervals during the treatment protocol. This periodic action allows for controlled enhancement of plasmid DNA uptake and cytokine expression while maintaining manageable protocol complexity through standardized pulse delivery schedules
3Reliability
If repeated delivery of recombinant IL-12 is administered daily, then maximal therapeutic activity is achieved, but dose-dependent toxicity increases
Solution Approach 1:
The patent replaces the mechanical administration of recombinant IL-12 protein with gene therapy delivery using plasmid DNA and electroporation. This substitution allows the body's own cells to produce IL-12 locally at the tumor site, achieving maximal therapeutic activity while avoiding the dose-dependent toxicity associated with repeated systemic administration of recombinant protein
4Productivity
If viral vectors are used for gene delivery, then gene transfer efficiency improves, but safety concerns and immune responses increase
Solution Approach 1:
The patent uses non-viral plasmid DNA as a temporary, disposable gene delivery vehicle instead of persistent viral vectors. The plasmid DNA provides sufficient gene transfer efficiency for local cytokine production but is ultimately degraded and eliminated by the body without causing long-term immune responses or safety concerns associated with viral integration
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This approach results in statistically significant improvements in tumor regression and long-term survival rates, with increased expression of IL-12 and IFN-γ, infiltration of immune cells, and inhibition of angiogenesis, effectively treating primary and metastatic tumors.
Implementation Method 1
In vivo electroporation is a gene delivery technique that has been used successfully for efficient delivery of plasmid DNA to many different tissues
Data Source
AI summary
In accordance with the present invention is provided a method of treating a subject having a cancerous tumor. The treatment protocol methodology includes injecting the cancerous tumor with an effective dose of plasmid coding for a therapeutic protein followed by administering electroporation therapy to the tumor, the electroporation therapy includes the administration of at least one high voltage, short duration pulse to the tumor.